Kyu-Sik Kim
Overview
Explore the profile of Kyu-Sik Kim including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
735
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhattarai S, Kim K, Tayara H, Chong K
Int J Mol Sci
. 2022 Oct;
23(20).
PMID: 36293050
Cancer is the second-leading cause of death worldwide, and therapeutic peptides that target and destroy cancer cells have received a great deal of interest in recent years. Traditional wet experiments...
2.
Oh I, Kim K, Kim Y, Park J, Yoo K, Do S, et al.
Psychosom Med
. 2018 Oct;
81(1):41-50.
PMID: 30371632
Objective: Patients with advanced cancer commonly experience multiple symptoms that present as groups or clusters. The present study aimed to examine whether hypothalamus-pituitary-adrenal (HPA) axis dysfunction underlies the concurrent multiple...
3.
Proportion and characteristics of transient nodules in a retrospective analysis of pulmonary nodules
Yu J, Lee B, Ju S, Kim E, Kim Y, Chi S, et al.
Thorac Cancer
. 2017 Sep;
3(3):224-228.
PMID: 28920303
Background: Pulmonary nodules manifest as pure or mixed ground glass opacities (GGOs), or solid nodules. Methods: We retrospectively surveyed 317 cases with pulmonary nodules to observe the proportion and predictive...
4.
Lee K, Chung M, Kim Y, Lee J, Kim K, Ryu J, et al.
Thorac Cancer
. 2017 Sep;
3(2):150-155.
PMID: 28920300
Background: The aim of this study was to evaluate the prevalence, risk factors, and survival of lung cancer in patients with idiopathic pulmonary fibrosis (IPF). Methods: IPF with lung cancer...
5.
Oh I, Ban H, Kim K, Song S, Na K, Kim Y, et al.
Thorac Cancer
. 2017 Sep;
3(1):19-26.
PMID: 28920258
Background: RRM1, the regulatory subunit of ribonucleotide reductase, is involved in carcinogenesis and the response to gemcitabine. Two single nucleotide polymorphisms (SNP) in the RRM1 gene (RR37 and RR524) impact...
6.
Ju S, Park H, Kang H, Park C, Kim W, Seon H, et al.
Thorac Cancer
. 2017 Sep;
4(4):405-409.
PMID: 28920229
Background: The National Lung Screening Trial revealed that low dose computed tomography (CT) screening reduced lung cancer mortality by 20%. However, nearly all (96.4%) of the positive screening results were...
7.
Heo S, Lee J, Kim S, Yun D, Park J, Kim K, et al.
Sci Rep
. 2017 May;
7(1):1516.
PMID: 28473719
An advanced organic photodetector (OPD) with a butter layer of Si-rich silicon oxynitride (SiON) was fabricated. The detector structure is as follows: Indium tin oxide (ITO) coated glass substrate/SiON(10 nm)/naphthalene-based...
8.
Park C, Oh I, Kim K, Choi Y, Jang T, Kim Y, et al.
Clin Lung Cancer
. 2017 Feb;
18(4):e289-e296.
PMID: 28185792
Introduction: To date, no prospective phase III trials have directly compared the efficacy of pemetrexed plus cisplatin (Pem-Cis) with docetaxel plus cisplatin (Doc-Cis) in patients with nonsquamous non-small-cell lung cancer....
9.
Oh I, Kim K, Park C, Kim Y, Lee K, Jeong J, et al.
BMC Cancer
. 2016 Aug;
16:690.
PMID: 27566413
Background: No novel chemotherapeutic combinations have demonstrated superior efficacy to etoposide/cisplatin (EP), a standard treatment regimen for extensive-stage small cell lung carcinoma (ES-SCLC) over the past decade. We aimed to...
10.
Ban H, Kim K, Oh I, Yoon S, Lee B, Yu J, et al.
Thorac Cancer
. 2016 Jan;
5(6):525-9.
PMID: 26767047
Background: Platinum doublets are standard first-line treatment for stage IV non-small cell lung cancer (NSCLC) without targetable driver mutations. Oxaliplatin is more potent than cisplatin, requiring fewer DNA adducts to...